SVB Leerink started coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report issued on Monday, February 10th, TipRanks reports. The firm set a “buy” rating and a $6.00 price target on the biopharmaceutical company’s stock. SVB Leerink’s price objective points to a potential upside of 92.31% from the stock’s current price. SVB Leerink also issued estimates for Abeona Therapeutics’ Q4 2019 earnings at ($0.23) EPS, FY2019 earnings at ($1.45) EPS, Q1 2020 earnings at ($0.33) EPS, Q2 2020 earnings at ($0.30) EPS, Q3 2020 earnings at ($0.28) EPS, Q4 2020 earnings at ($0.27) EPS, FY2020 earnings at ($1.17) EPS, FY2021 earnings at ($1.01) EPS and FY2022 earnings at ($0.98) EPS.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald initiated coverage on shares of Abeona Therapeutics in a report on Tuesday, December 10th. They set a “hold” rating and a $4.00 target price for the company. ValuEngine upgraded shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Zacks Investment Research cut shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. HC Wainwright assumed coverage on shares of Abeona Therapeutics in a research note on Tuesday, January 21st. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Mizuho reaffirmed a “hold” rating and issued a $4.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $7.38.

ABEO stock traded down $0.17 during trading hours on Monday, hitting $3.12. 15,796 shares of the stock traded hands, compared to its average volume of 1,954,380. The stock has a 50-day simple moving average of $2.95 and a 200 day simple moving average of $2.78. Abeona Therapeutics has a one year low of $1.46 and a one year high of $8.41. The company has a market cap of $160.63 million, a P/E ratio of -1.96 and a beta of 1.50. The company has a current ratio of 2.45, a quick ratio of 2.45 and a debt-to-equity ratio of 0.07.

In related news, Director Stefano Buono bought 200,000 shares of Abeona Therapeutics stock in a transaction that occurred on Tuesday, December 24th. The stock was purchased at an average cost of $2.50 per share, for a total transaction of $500,000.00. Following the acquisition, the director now owns 270,000 shares in the company, valued at $675,000. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 33.60% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northern Trust Corp raised its stake in Abeona Therapeutics by 2.0% during the 2nd quarter. Northern Trust Corp now owns 408,134 shares of the biopharmaceutical company’s stock valued at $1,951,000 after purchasing an additional 7,824 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new position in Abeona Therapeutics during the second quarter worth $74,000. BlackRock Inc. raised its stake in Abeona Therapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 2,459,931 shares of the biopharmaceutical company’s stock worth $11,759,000 after acquiring an additional 137,558 shares in the last quarter. Vanguard Group Inc. raised its stake in Abeona Therapeutics by 11.8% during the second quarter. Vanguard Group Inc. now owns 1,828,699 shares of the biopharmaceutical company’s stock worth $8,742,000 after acquiring an additional 193,618 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in Abeona Therapeutics during the second quarter worth $196,000.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Read More: What does a market perform rating mean?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.